Biomarin Pharmaceutical (BMRN) Income from Continuing Operations (2009 - 2026)
Biomarin Pharmaceutical (BMRN) recorded quarterly Income from Continuing Operations of 105527000.0 in Q1 2026, up 326.58% on a QoQ basis from 46573000.0 in Q4 2025, and down 43.17% year-over-year from 185686000.0 in Q1 2025.
Biomarin Pharmaceutical (BMRN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 105527000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 43.17% year-over-year to 105527000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 268742000.0 (down 48.7% YoY) and the FY2025 annual result came in at 348901000.0, down 18.26% from the prior year.
- Income from Continuing Operations advanced to 105527000.0 in Q1 2026, from 46573000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 240532000.0 in Q2 2025 and troughed at 46573000.0 in Q4 2025.
- A 5-year average of 70029000.0 and a median of 56040000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 8282.73% — and 2025, when it slumped 137.28%.
- Tracing BMRN's Income from Continuing Operations over 5 years: stood at 249000.0 in 2022, then surged by 8282.73% to 20375000.0 in 2023, then soared by 513.22% to 124943000.0 in 2024, then sank by 137.28% to 46573000.0 in 2025, then surged by 326.58% to 105527000.0 in 2026.
- Business Quant data shows BMRN's Income from Continuing Operations at 105527000.0 in Q1 2026, 46573000.0 in Q4 2025, and 30744000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn | 105.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.53 Mn |
| Dec 31, 2025 | -46.57 Mn |
| Sep 30, 2025 | -30.74 Mn |
| Jun 30, 2025 | 240.53 Mn |
| Mar 31, 2025 | 185.69 Mn |
| Dec 31, 2024 | 124.94 Mn |
| Sep 30, 2024 | 106.08 Mn |
| Jun 30, 2024 | 107.17 Mn |
| Mar 31, 2024 | 88.66 Mn |
| Dec 31, 2023 | 20.38 Mn |
| Sep 30, 2023 | 40.38 Mn |
| Jun 30, 2023 | 56.04 Mn |
| Mar 31, 2023 | 50.85 Mn |
| Dec 31, 2022 | -249,000.00 |
| Sep 30, 2022 | -6.65 Mn |
| Jun 30, 2022 | 27.66 Mn |
| Mar 31, 2022 | 120.80 Mn |
| Dec 31, 2021 | -57.90 Mn |
| Sep 30, 2021 | -36.49 Mn |
| Jun 30, 2021 | 12.94 Mn |